Research Analysts Offer Predictions for Stryker Q2 Earnings

Stryker Co. (NYSE:SYK - Free Report) - Roth Capital dropped their Q2 2025 earnings per share (EPS) estimates for Stryker in a research report issued to clients and investors on Thursday, May 1st. Roth Capital analyst J. Wittes now expects that the medical technology company will post earnings per share of $3.04 for the quarter, down from their previous estimate of $3.13. The consensus estimate for Stryker's current full-year earnings is $13.47 per share. Roth Capital also issued estimates for Stryker's Q3 2025 earnings at $3.25 EPS, Q4 2025 earnings at $4.32 EPS, FY2025 earnings at $13.45 EPS, Q2 2026 earnings at $3.52 EPS, Q3 2026 earnings at $3.65 EPS and Q4 2026 earnings at $4.66 EPS.

A number of other equities analysts also recently commented on SYK. Royal Bank of Canada raised their price objective on shares of Stryker from $425.00 to $435.00 and gave the stock an "outperform" rating in a report on Wednesday, January 29th. Canaccord Genuity Group boosted their target price on shares of Stryker from $420.00 to $435.00 and gave the stock a "buy" rating in a research note on Wednesday, January 29th. JMP Securities reaffirmed a "market perform" rating on shares of Stryker in a report on Tuesday, February 18th. Wells Fargo & Company lifted their target price on Stryker from $427.00 to $435.00 and gave the company an "overweight" rating in a research note on Wednesday, January 29th. Finally, StockNews.com lowered Stryker from a "buy" rating to a "hold" rating in a research report on Thursday, March 6th. Five equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $426.53.

Stryker Stock Performance

Shares of NYSE SYK opened at $378.60 on Monday. The business's 50 day moving average is $366.38 and its two-hundred day moving average is $373.92. The company has a market cap of $144.51 billion, a P/E ratio of 48.79, a P/E/G ratio of 2.93 and a beta of 0.93. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. Stryker has a 12 month low of $314.93 and a 12 month high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical technology company reported $2.84 earnings per share for the quarter, beating analysts' consensus estimates of $2.73 by $0.11. The business had revenue of $5.87 billion for the quarter, compared to the consensus estimate of $5.68 billion. Stryker had a return on equity of 23.58% and a net margin of 13.25%. The firm's revenue was up 11.9% compared to the same quarter last year. During the same period last year, the business earned $2.50 EPS.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st were issued a dividend of $0.84 per share. The ex-dividend date was Monday, March 31st. This represents a $3.36 annualized dividend and a yield of 0.89%. Stryker's dividend payout ratio (DPR) is currently 45.41%.

Insider Buying and Selling at Stryker

In related news, Director Allan C. Golston sold 2,458 shares of the company's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the transaction, the director now directly owns 14,895 shares of the company's stock, valued at approximately $5,705,827.65. This represents a 14.16 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 5.90% of the company's stock.

Institutional Trading of Stryker

Institutional investors have recently modified their holdings of the company. Norges Bank acquired a new stake in shares of Stryker in the fourth quarter valued at approximately $1,710,744,000. GAMMA Investing LLC boosted its position in Stryker by 43,226.8% during the first quarter. GAMMA Investing LLC now owns 2,074,922 shares of the medical technology company's stock valued at $772,390,000 after purchasing an additional 2,070,133 shares during the last quarter. Raymond James Financial Inc. bought a new position in Stryker in the fourth quarter valued at approximately $353,394,000. FMR LLC increased its position in shares of Stryker by 10.0% during the 4th quarter. FMR LLC now owns 8,034,844 shares of the medical technology company's stock worth $2,892,946,000 after purchasing an additional 727,850 shares during the last quarter. Finally, Proficio Capital Partners LLC raised its stake in shares of Stryker by 52,520.8% during the 4th quarter. Proficio Capital Partners LLC now owns 596,194 shares of the medical technology company's stock worth $214,660,000 after purchasing an additional 595,061 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.